Characterizing Medicare Medication Therapy Management program enrollees with central nervous system–active polypharmacy

More than 1 in 10 MTM enrollees experience CNS-active polypharmacy, which is higher than the general Medicare fee-for-service beneficiary population. MTM enrollees with CNS-active polypharmacy are more likely to be male, dually enrolled in Medicaid, and with greater comorbidity burden and prior-year use of health care and medications, suggesting that interventions for this population may need to account for additional clinical and socioeconomic needs. Despite being at greater risk of adverse drug events including impaired cognition and falls, just over one-third of MTM enrollees with CNS-active polypharmacy participate in a CMR, suggesting opportunity for more targeted outreach and intervention by MTM programs, Part D plan sponsors, and Centers for Medicare & Medicaid Services.

Authors

Institutions

Publication Details

Journal
Journal of Managed Care & Specialty Pharmacy
Published
2025-12-24
DOI
https://doi.org/10.18553/jmcp.2026.32.1.85
Citations
1
Primary Topic
Pharmaceutical Practices and Patient Outcomes
Type
article
Field-Weighted Citation Impact
1.22
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Characterizing Medicare Medication Therapy Management program enrollees with central nervous system–active polypharmacy

Caroline E. Sloan, Timothy S. Anderson, Matthew L. Maciejewski, Anna Hung et al.
1 citations
Journal of Managed Care & Specialty Pharmacy
Pharmaceutical Practices and Patient Outcomes
1.22
article

Characterizing Medicare Medication Therapy Management program enrollees with central nervous system–active polypharmacy

Caroline E. Sloan, Timothy S. Anderson, Matthew L. Maciejewski, Anna Hung, Juliessa M. Pavon, Lauren E. Wilson, Susan N. Hastings, Oliver Valdez, Richard Erickson, Nicole Brandt, Valerie A. Smith, Melissa Castora-Binkley, Kelli Tharpe
article en
1 citations

Abstract

More than 1 in 10 MTM enrollees experience CNS-active polypharmacy, which is higher than the general Medicare fee-for-service beneficiary population. MTM enrollees with CNS-active polypharmacy are more likely to be male, dually enrolled in Medicaid, and with greater comorbidity burden and prior-year use of health care and medications, suggesting that interventions for this population may need to account for additional clinical and socioeconomic needs. Despite being at greater risk of adverse drug events including impaired cognition and falls, just over one-third of MTM enrollees with CNS-active polypharmacy participate in a CMR, suggesting opportunity for more targeted outreach and intervention by MTM programs, Part D plan sponsors, and Centers for Medicare & Medicaid Services.

Journal of Managed Care & Specialty PharmacyVol. 32(1)
University of Maryland, Baltimore (US), California State University System (US), University of Pittsburgh (US), Duke University (US), Geriatric Research Education and Clinical Center (US), Durham VA Health Care System (US), Duke Institute for Health Innovation (US), VA Pittsburgh Healthcare System (US), National Institute on Aging (US), National Patient Safety Foundation (US)
Openalex Percentile: Top 15%
Pharmaceutical Practices and Patient Outcomes
1.22
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.